证券代码：001376 证券简称：百通能源 公告编号：2025- 江西百通能源股份有限公司 前次募集资金使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会（以下简称"证监会"）发布的《上市公司证 券发行注册管理办法》《监管规则适用指引——发行类第 7 号》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求）》等相关规定，江西 百通能源股份公司（以下简称"公司"）董事会编制了截至 2025 年 3 月 31 日的 《江西百通能源股份有限公司前次募集资金使用情况专项报告》： 一、前次募集资金的募集及存放情况 经证监会《关于核准江西百通能源股份有限公司首次公开发行股票的批复》 （证监许可20222640 号）核准，并经深圳证券交易所同意，本公司由主承销商 天风证券股份有限公司于 2023 年 10 月 25 日向社会公众公开发行普通股（A 股） 股票 4,609 万股，每股面值 1 元，每股发行价人民币 4.56 元。截至 2023 年 10 月 31 日止，本公司共募集资金 210,170,400.0 ...

Group 1 - The core point of the article is the special report on the use of previously raised funds by Yongtaiyun Chemical Logistics Co., Ltd., detailing the amount raised, its allocation, and changes in investment projects [1][2][6]. Group 2 - The amount of funds raised was 79,104.62 million RMB from the issuance of 25.97 million shares at a price of 30.46 RMB per share, with a net amount of 67,170.18 million RMB after deducting fees [2][4]. - As of March 31, 2025, the remaining balance of the raised funds was 12,046.13 million RMB, which includes interest income and fees [22][18]. - The company has made changes to its investment projects, including reallocating funds from the chemical logistics equipment purchase project to acquire 100% of Tianjin Hanuowei International Logistics Co., Ltd. [8][9]. Group 3 - The company has engaged in cash management using temporarily idle funds, with a maximum of 50,000 million RMB approved for cash management activities [16][17]. - The company temporarily supplemented working capital with idle funds, totaling 14,000 million RMB, of which 10,000 million RMB has been returned to the special fund account [20][21]. Group 4 - The investment projects have shown varying degrees of effectiveness, with some projects achieving profits below the promised levels due to market fluctuations and competition [21][24]. - The "Ningbo Logistics Center Upgrade Project" has reached its intended use status, generating a net profit of 870.85 million RMB, exceeding the expected profit [23][24].

Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Huizhou EVE Energy Co., Ltd., confirming compliance with regulatory guidelines and reflecting the company's financial management practices [1][2][3]. Fundraising Overview - In 2020, the company raised approximately RMB 2.5 billion by issuing 48,440,224 shares at a price of RMB 51.61 per share, with a net amount of RMB 2.48 billion after deducting issuance costs [3]. - In 2022, the company raised RMB 9 billion by issuing 142,970,611 shares at a price of RMB 62.95 per share, with the funds received on November 24, 2022 [3]. Fund Management - The company has established a special account management system for the raised funds to ensure their proper use, in compliance with relevant laws and regulations [3][4]. - As of December 31, 2024, the balance of the special account for the 2020 fundraising was RMB 14.31 million, while the balance for the 2022 fundraising was RMB 677.53 million [9]. Fund Utilization - By December 31, 2024, the total amount utilized from the 2020 fundraising was RMB 2.38 billion, while RMB 6.58 billion was utilized from the 2022 fundraising [5][6]. - The company has made adjustments to the use of funds, reallocating some to the "Passenger Vehicle Power Battery Project (Phase III)" [5][6]. Investment Projects - The company committed to invest RMB 897.36 million in various projects, with actual investments amounting to RMB 657.58 million, resulting in a difference of RMB 239.78 million primarily due to ongoing payments for the "Passenger Vehicle Lithium-ion Battery Project" [6][10]. - The projects include the "HBF16GWh Passenger Vehicle Lithium-ion Battery Project," which has reached its intended operational status, with some payments pending [6][10]. Financial Performance - The report indicates that the actual investment amounts align with the disclosed information, with no discrepancies noted in the fundraising utilization compared to previous disclosures [11].

Group 1 - The company held its ninth meeting of the fourth Supervisory Board on June 6, 2025, with all three supervisors present, complying with relevant regulations [1][2] - The Supervisory Board approved the proposal to conclude and adjust certain fundraising projects, reallocating a total of 160.8871 million yuan (10,821.10 million yuan in surplus funds and 5,267.61 million yuan in remaining over-raised funds) to a new project, "Intelligent Cloud Service Construction and Operation Project" [1][2] - The decision to change the fundraising projects is aligned with the company's overall development strategy and aims to enhance the efficiency of fundraising utilization, benefiting all shareholders and meeting long-term development needs [2] Group 2 - The proposal's review process adhered to the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring the legality and validity of the voting results [2] - The voting outcome was unanimous, with 3 votes in favor and no opposition or abstentions, indicating strong support for the proposal [2] - The proposal will be submitted for further review at the company's shareholders' meeting [2]

证券代码：688520 证券简称：神州细胞 公告编号：2025-023 北京神州细胞生物技术集团股份公司 前次募集资金使用情况报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 前次募集资金基本情况 （一）首次公开发行股票 根据中国证券监督管理委员会于 2020 年 4 月 29 日出具的证监许可2020815 号文《关于同意北京神州细胞生物技术集团股份公司首次公开发行股票注册的批 复》，北京神州细胞生物技术集团股份公司（以下简称"公司"或"本公司"）获 准向境内投资者首次公开发行人民币普通股 5,000.00 万股，发行价格为每股人民 币 25.64 元。本次公开发行股票募集资金总额为人民币 1,282,000,000.00 元，扣 除承销费人民币 60,971,940.00 元（不含增值税）后，实际收到募集资金人民币 值税）后，实际募集资金净额为人民币 1,201,173,211.41 元。前述募集资金于 2020 年 6 月 15 日到位，经普华永道中天会计师事务所（特殊普通合伙）予以验证并 出具了普华永道中 ...

Core Viewpoint - The company, Xiamen Qianzhao Optoelectronics Co., Ltd., is utilizing bank acceptance bills, letters of credit, and its own foreign exchange to pay for fundraising investment projects and replace the funds with an equivalent amount of raised funds, which is deemed beneficial for improving fund utilization efficiency and reducing financial costs [1][4]. Summary by Sections Fundraising Basic Situation - The company issued 187,500,000 A-shares at a price of RMB 8.00 per share, raising a total of RMB 1,500,000,000, with a net amount of RMB 1,479,236,230.55 after deducting issuance costs [1]. Payment Operation Process - **Bank Acceptance Bills**: The company establishes a detailed ledger for payments made via bank acceptance bills, submits payment applications, and compiles monthly summaries for reporting to the sponsor [2]. - **Letters of Credit**: Similar procedures are followed for letters of credit, including establishing a detailed ledger and compiling monthly summaries for the sponsor [3]. - **Foreign Exchange Payments**: The company also follows a structured process for foreign exchange payments, maintaining a detailed ledger and reporting to the sponsor [4]. Impact on the Company and Subsidiaries - The use of these payment methods is expected to enhance the efficiency of fund utilization, lower financial costs, and optimize payment methods for investment projects, aligning with the interests of the company and its shareholders [4]. Approval Procedures and Opinions - The company has undergone necessary decision-making processes, with the relevant proposals approved by the board of directors and the supervisory board [5].

证券代码：300102 证券简称：乾照光电 公告编号：2025-057 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 厦门乾照光电股份有限公司（以下简称"公司"）第六届监事会第十一次会 议于 2025 年 6 月 3 日（星期二）下午以现场会议的方式在公司会议室召开，会 议通知于 2025 年 5 月 22 日以电子邮件等方式通知全体监事，会议应出席监事 3 名，实际出席监事 3 名。会议的召集和召开符合《中华人民共和国公司法》和《厦 门乾照光电股份有限公司章程》的有关规定，会议由监事会主席王晓婷女士主持。 二、监事会会议审议情况 具体内容请详见公司刊登于巨潮资讯网（www.cninfo.com.cn）的相关公告。 表决结果：3 名与会监事，3 票同意，0 票反对，0 票弃权，获得通过。 （三）审议通过《关于公司终止与关联方共同投资的议案》 经审核，监事会认为：公司本次终止与关联方共同投资事项是经综合研判和 慎重考虑，结合各合作方的实际情况，基于审慎使用资金的原则，并为了降低投 资风险及管理成本保护资金安全，不会对公司日常生产经营造成 ...

Core Viewpoint - Guangdong Naruida Radar Technology Co., Ltd. is making significant adjustments to its corporate governance and organizational structure to enhance operational efficiency and align with its strategic goals [3][6][38]. Group 1: Corporate Governance and Organizational Changes - The company has revised its Articles of Association to improve operational efficiency, with the changes pending approval from the shareholders' meeting [1][2]. - An organizational restructuring has been approved to optimize internal management and ensure stable business development [3][6]. Group 2: Fund Management and Financial Activities - The company plans to use up to RMB 300 million of idle raised funds to temporarily supplement its working capital, with a usage period not exceeding 12 months [6][10]. - The total amount raised from the initial public offering was approximately RMB 1.804 billion, with a net amount of RMB 1.654 billion after deducting issuance costs [6][8]. Group 3: Shareholder Meeting and Voting Procedures - The company will hold its first extraordinary general meeting of 2025 on June 16, 2025, with both onsite and online voting options available for shareholders [14][15]. - The meeting will address various proposals, including those related to asset restructuring and governance adjustments [18][20]. Group 4: Investment and Expansion Plans - The company is in the process of acquiring 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of share issuance and cash payment, along with raising matching funds [32][38]. - A wholly-owned subsidiary has been established in Hong Kong to enhance international presence and attract global talent, with a registered capital of HKD 10 million [46][48].

Core Viewpoint - The company plans to use bank acceptance bills and letters of credit to pay for part of the fundraising projects and will replace these payments with the raised funds, aiming to improve the efficiency of fund usage and reduce financial costs [1][7][9]. Fundraising Basic Situation - The company raised a total of RMB 75,438.20 million by issuing 51.67 million shares at RMB 14.60 per share, with actual funds received amounting to RMB 67,582.85 million after deducting issuance costs of RMB 7,855.35 million [1][2]. Fundraising Investment Project Situation - The company approved the use of RMB 57 million of excess funds to repay bank loans and made changes to the implementation of fundraising projects without altering the investment direction or total amount [2][3]. - The company has also approved the use of remaining funds from the "Kunshan Hanjing Precision Connector Production Project" for new projects, including "Semiconductor Metal Heat Sink Material Project" and "Automotive High-Frequency Signal Cable and Connector Project" [3][4]. Use of Bills and Letters of Credit - The company intends to use bank acceptance bills and letters of credit for payments, which will be replaced by the raised funds, following an internal approval process to ensure compliance and efficiency [6][7]. Impact on Daily Operations - The use of these financial instruments is expected to lower financial costs and enhance the flexibility of fund usage without affecting the normal progress of fundraising projects [7][9]. Approval Procedures and Opinions - The board and supervisory committee have reviewed and approved the use of bank acceptance bills and letters of credit, confirming that this does not change the direction of the raised funds and supports efficient fund usage [7][8].

Summary of Key Points Core Viewpoint - The company, Aibono Medical Technology Co., Ltd., is utilizing funds raised from a simplified issuance of shares to provide loans to its subsidiary, Tianyan Pharmaceutical, for the implementation of investment projects, ensuring compliance with regulatory requirements and maintaining the integrity of the fundraising purpose [1][4][5]. Fundraising Overview - The company plans to issue 3,593,615 shares at a price of 79.20 RMB per share, raising a total of 284,614,308 RMB, which will be used for specific investment projects [1][2]. - The total investment amount for the projects is 422,430,700 RMB, with 284,614,308 RMB allocated from the raised funds [2]. Investment Project Details - The funds will be allocated to various projects, with a total planned investment of 422,430,700 RMB, and the intended use of raised funds amounting to 284,614,308 RMB [2]. - The company may adjust the investment sequence and amounts based on project progress and funding needs, with any shortfall covered by self-raised funds [2]. Loan Provision to Subsidiary - The company intends to provide a loan of up to 260,000,000 RMB to Tianyan Pharmaceutical for the construction of an "invisible lens and injection mold processing production line" [3][4]. - The loan will be disbursed in batches based on project progress and actual funding needs, with interest rates determined by the latest published LPR [3][4]. Subsidiary Information - Tianyan Pharmaceutical, established on September 23, 2015, has a registered capital of 37,500,000 RMB and operates in pharmaceutical technology research and medical device production [3]. - As of December 31, 2024, Tianyan Pharmaceutical reported total assets of 541,571,200 RMB, total liabilities of 461,288,700 RMB, and a net profit of 7,607,000 RMB [3]. Purpose and Impact of the Loan - The loan aims to support the implementation of investment projects, aligning with the company's strategic planning and long-term interests without altering the intended use of raised funds [4][5]. - The management of the funds will adhere to strict regulatory protocols, ensuring effective oversight and compliance with relevant laws [4][5]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the loan provision, confirming that it meets legal and regulatory standards and aligns with the company's long-term development needs [5][6].